WHO greenlights Takeda's dengue vaccine as company plans to 're-engage' with FDA

2024-05-15
EndPoints
疫苗紧急使用授权临床研究上市批准
The World Health Organization prequalified Takeda’s new dengue vaccine on Wednesday, a year after the company withdrew its FDA application for the candidate — though the company now says it will soon “re-engage” with the FDA.
The WHO wrote in a statement that the vaccine, known as TAK-003 or Qdenga, is recommended for children 6 to 16 years old in areas with a burden and transmission of dengue, adding that the vaccine should be administered in a two-dose schedule with a three-month interval between doses.
WHO greenlights Takeda's dengue vaccine as company plans to 're-engage' with FDA
Preview
来源: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。